Ocugen, Inc..
OCGN.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing therapies to cure blindness diseases. The company is developing gene therapies to potentially address inherited retinal diseases such as retinitis pigmentosa and Leber congenital amaurosis. Ocugen is ...Show More
Better Health for All
30
Ocugen's core business is developing gene therapies for blindness diseases, with its entire pipeline focused on these treatments. Clinical trial data for OCU400, OCU410ST, and OCU410 show statistically significant improvements in visual function and/or slower disease progression, with 100% of treated evaluable subjects in the OCU400 Phase 1/2 trial showing improvement or preservation of visual function.
1
The company has no revenue from products with established negative health outcomes.
2
The OCU400 Phase 1/2 trial reported no serious adverse events (SAEs) over two years, indicating a perfect safety record for this specific trial.
3
Research and development expenses increased from $6.8 million in Q1 2024 to $9.5 million in Q1 2025, representing 59.4% of total operating expenses in Q1 2025.
4
The company aims to serve 300,000 retinitis pigmentosa (RP) patients in the US and Europe, and 1.6 million globally, and has an FDA-approved Expanded Access Program (EAP) for OCU400 for adults with early, intermediate to advanced RP.
5
OCU400, OCU410ST, and OCU410 have received ATMP classification from the EMA, which can accelerate regulatory review, and OCU400 has Orphan Drug and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA.
6
The Phase 3 liMeliGhT trial for OCU400 is designed with 150 participants, randomized 2:1 to treatment and control groups, including patients with diverse gene mutations.
7
Fair Money & Economic Opportunity
0
Ocugen, Inc. is a biopharmaceutical company focused on developing gene therapies and vaccines. Its business operations, as described in the provided articles, do not involve lending, insuring, moving, or storing money, nor does it offer financial products or services to consumers. Consequently, all Key Performance Indicators (KPIs) related to 'Fair Money & Economic Opportunity' are not applicable to the company's activities.
Fair Pay & Worker Respect
-20
Employee engagement, based on Glassdoor reviews, is rated 2.7 out of 5 stars, which is approximately 54%.
1
Additionally, 39% of employees would recommend working at Ocugen to a friend.
2
Compensation and benefits received a rating of 3.2 out of 5 stars, showing a 3% improvement over the last 12 months.
3
The company provides free breakfast and lunch for all employees.
4
Ocugen states it is an equal opportunity employer and complies with applicable federal, state, and local non-discrimination laws.
5
The company also reports no existing or threatened labor disturbances or disputes with employees.
6
Furthermore, material employee benefit plans are maintained in compliance with ERISA and the Internal Revenue Code.
7
The company is actively seeking an Environmental Health and Safety Manager to manage incident investigations and implement corrective actions.
8
Fair Trade & Ethical Sourcing
0
No evidence available to assess Ocugen, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-20
Ocugen intends to restate its consolidated financial statements for the year ended December 31, 2022, and will include restated unaudited financial information for the first three quarters of 2023 and 2022.
1
This restatement is due to accounting errors in the application of U.S. Generally Accepted Accounting Principles (GAAP) to certain collaboration agreements, and the company identified a material weakness in its internal control over financial reporting.
2
The restated periods cover financial statements from January 1, 2020, up to the third quarter of 2023.
3
The company's financial statements are subject to audit by Ernst & Young LLP.
4
Kind to Animals
0
No information was found in the provided articles regarding Ocugen, Inc.'s animal testing practices, cruelty-free certifications, use of animal-derived ingredients, humane certifications for operations, wildlife conservation impact, supplier audits for welfare, cage-free sourcing, R&D investment in animal-free alternatives, animal agriculture ethics, animal-free R&D collaborations, or public policy engagement related to animal welfare.
No War, No Weapons
0
No evidence available to assess Ocugen, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No evidence available to assess Ocugen, Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
No specific, quantitative evidence was found in the provided articles to assess Ocugen, Inc.'s performance against any of the KPIs for the 'Respect for Cultures & Communities' ethical value. The articles reviewed primarily contained financial information or general statements about company culture without concrete data points relevant to community engagement, cultural preservation, or related metrics.
Safe & Smart Tech
0
Ocugen's privacy policy states that users have rights to access, rectify, erase, and transfer their data, and can opt-out of commercial emails.
1
The company indicates that data is kept for a reasonable time for communication, service provision, legal compliance, and dispute resolution.
2
Furthermore, the policy explicitly mentions compliance with applicable laws, including the CCPA.
3
Zero Waste & Sustainable Products
0
No evidence was found in the provided articles regarding Ocugen, Inc.'s performance on any of the 'Zero Waste & Sustainable Products' KPIs.
1
The articles primarily focus on the company's biotechnology operations and financial reporting, with no mention of waste diversion rates, product recyclability, packaging sustainability, or any other related initiatives.
2